The field of gene-editing therapy is a rapidly evolving frontier with the potential to transform the treatment of both rare and common diseases. By modifying genetic material to silence or reactivate specific genes, these therapies offer the promise of durable, lifelong health benefits. However, transitioning from laboratory discovery to clinical practice requires navigating a complex […]
The CVC is pleased to announce that Cindy Westerhout, PhD, has been appointed as Adjunct Professor of Medicine (Cardiology) at the University of Alberta. Dr. Westerhout currently serves as the Associate Director (Research & Strategy), Clinical Trial Statistics at the CVC and is a co-founder of the Biomedical AnaLytics Studio And Methods Unit (BALSAM). This […]
A myocardial infarction (MI), or heart attack, occurs when heart muscle cells die from oxygen deprivation. Type 1 (T1MI) is typically caused by a blood clot within a coronary artery, whereas Type 2 (T2MI) results from an imbalance between oxygen supply and demand in the cardiac tissue. Distinguishing between the two is challenging in practice […]
New research from the STREAM-1 and -2 clinical trials underscores a critical window for treating ST-elevation myocardial infarction (STEMI)—a severe heart attack caused by a completely blocked artery. Although the benefits of reperfusion (restoring blood flow) are known to be time-dependent, this study focused on the specific clinical outcomes of performing primary percutaneous coronary intervention (PPCI)—an emergency […]
We are pleased to share the 2025 Canadian VIGOUR Centre (CVC) Annual Report, “The Arteries of Innovation.” Much like an arterial system, innovation thrives on the convergence of diverse ideas, circulating insights from a multitude of sources to maintain a vital, continuous flow. At the CVC, we are dedicated to translating complex, high-quality data into […]
Dr. Arnav Agarwal is an academic general internal medicine physician and Assistant Professor at the University of Alberta and University of Alberta Hospital. He completed his medical training and internal medicine residency at the University of Toronto, followed by a clinical fellowship in general internal medicine at McMaster University. He is currently completing a PhD […]
In this JAMA Cardiology viewpoint, Drs. Paul Armstrong, Kevin Bainey, and Christopher Granger argue that total ischemic time—the interval from symptom onset to the restoration of blood flow—is the most critical factor in surviving a severe heart attack, known as an ST-elevation myocardial infarction (STEMI). While the gold standard treatment is percutaneous coronary intervention (PCI), its life-saving […]
Although an interventional cardiology procedure called primary percutaneous coronary intervention (PCI) is the gold standard for treating a severe heart attack—known as an ST-segment elevation myocardial infarction (STEMI)—its success is highly time-dependent. Current oral medications are often absorbed too slowly to provide immediate protection during transit to the hospital and the actual PCI procedure, creating […]
Patients undergoing maintenance dialysis for kidney failure face a substantial risk of cardiovascular disease and death, yet relatively few proven preventive therapies currently exist. To address this gap, an international team—including CVC Faculty Member Dr. David Collister—conducted the ACHIEVE trial, a randomized controlled study investigating whether the heart failure medication spironolactone, as compared to placebo, could reduce […]
For patients experiencing a type of major heart attack known as ST-Segment Elevation Myocardial Infarction (STEMI), the standard treatment is a primary percutaneous coronary intervention (PCI) to clear the blocked artery. However, in about half of these cases, fragments of the blood clot break off and cause new blockages in smaller vessels downstream—a complication known […]
